drugset / Trial / NCT06914206

Esketamine Combined With PRF of DRG for Acute/Subacute Zoster-associated Pain

NCT06914206

RandomizedParallel-groupSingle-blindTreatment

Summary

To assess the 1-month effects and safety of esketamine - PRF -standardized drug treatment against PRF -standardized drug treatment acute/subacute zoster-associated pain (ZAP) patients.

Timeline

Start
2025-04-01
Primary completion
2026-04-01
Completion
2026-07-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified Intravenous

Indications